EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Olfactory Mucosal Mesenchymal Stem Cell‐Derived Exosomal LncA2M ‐ AS1 Ameliorates Parkinson's Disease by Regulating Microglial Glucose Metabolic Reprogramming and Neuroinflammation via the CFL1 / ROCK1 Axis

Jiangshan Zhang, Guoshuai Yang, Yanhui Zhou, Dan Hou, Chuang Wang, Yujie Hu, Ying Xia iD

CNS Neuroscience & Therapeutics · 2026-07 · 32 (7)

DOI: 10.1002/cns.71019 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 10.07.2026. Verfasst von Jiangshan Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, Hainan Province, P. R. China. Hauptthemen laut MEDLINE: Exosomes, rho-Associated Kinases, Mesenchymal Stem Cells, Microglia. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Joint Program on Health Science & Technology Innovation of Hainan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Parkinson's disease (PD), a common neurodegenerative condition, afflicts patients through the progressive degeneration of dopaminergic neurons and sustained neuroinflammation. This study investigates the role of olfactory mucosa‐derived mesenchymal stem cell (OM‐MSC)‐derived exosomes, particularly the long non‐coding RNA A2M‐AS1 (lncA2M‐AS1), in modulating microglial metabolism reprogramming and neuroinflammation in PD.

Methods

A mouse PD model was established using MPTP injections. Animals received treatments including OM‐MSC‐derived exosomes knockdown for lncA2M‐AS1 or AAV‐mediated lncA2M‐AS1 overexpression. Motor function was assessed using the open field test and the apomorphine‐induced rotation test. Glycolytic metabolism was evaluated by measuring ECAR and OCR using Seahorse XFp Analyzer, and the expression of glycolytic proteins (GLUT1, HK2, PKM2, LDHA) via Western blot. Molecular analyses included qPCR, Western blot, Co‐IP, and ubiquitination assays that were performed to investigate the lncA2M‐AS1/CFL1/ROCK1 regulatory axis. Histological examinations involved immunohistochemistry for TH and IBA1. The expressions of lncA2M‐AS1 and ROCK1 were determined in serum obtained from individuals with PD and matched controls.

Results

LncA2M‐AS1 is downregulated in PD patient serum and MPTP mice. OM‐MSC exosomal lncA2M‐AS1 suppressed microglial glycolysis, reduced pro‐inflammatory cytokine release, enhanced neuronal viability, and improved motor function in PD mice. Mechanistically, lncA2M‐AS1 directly binds to CFL1 mRNA, promoting ubiquitin‐mediated degradation of ROCK1 and inhibiting the CFL1/ROCK1 pathway. Knockdown of CFL1 or overexpression of lncA2M‐AS1 attenuated microglial activation and neuroinflammation, whereas ROCK1 overexpression reversed these protective effects.

Conclusion

OM‐MSC exosomal lncA2M‐AS1 ameliorates PD pathogenesis by targeting the CFL1/ROCK1 axis to reprogram microglial glucose metabolism and suppress neuroinflammation, offering a novel therapeutic strategy for PD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Exosomesrho-Associated KinasesMesenchymal Stem CellsMicrogliaOlfactory MucosaNeuroinflammatory DiseasesGlucoseAnimalsMiceMaleMice, Inbred C57BLHumans

Stichwörter der Autor:innen

Parkinson's diseaseexosomeslncA2M‐AS1microglial metabolismneuroinflammationolfactory mucosa mesenchymal stem cell

Substanzen

rho-Associated KinasesGlucoseRock1 protein, mouse

Autor:innen und Institutionen

  • Department of Neurology, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, Hainan Province, P. R. China.
  • Department of Neurosurgery, Central South University Xiangya School of Medicine Affiliated Haikou Hospital, Haikou, Hainan Province, P. R. China.

ORCID-Profile: Ying Xia

Förderung

  • Joint Program on Health Science & Technology Innovation of Hainan Province

Zitieren

APA

Zhang, J., Yang, G., Zhou, Y., Hou, D., Wang, C., Hu, Y., & Xia, Y. (2026). Olfactory Mucosal Mesenchymal Stem Cell‐Derived Exosomal LncA2M ‐ AS1 Ameliorates Parkinson's Disease by Regulating Microglial Glucose Metabolic Reprogramming and Neuroinflammation via the CFL1 / ROCK1 Axis. CNS Neuroscience & Therapeutics, 32(7). https://doi.org/10.1002/cns.71019

Vancouver

Zhang J, Yang G, Zhou Y, Hou D, Wang C, Hu Y, et al. Olfactory Mucosal Mesenchymal Stem Cell‐Derived Exosomal LncA2M ‐ AS1 Ameliorates Parkinson's Disease by Regulating Microglial Glucose Metabolic Reprogramming and Neuroinflammation via the CFL1 / ROCK1 Axis. CNS Neuroscience & Therapeutics. 2026;32(7). doi:10.1002/cns.71019

BibTeX
@article{Zhang2026,
  author = {Zhang, Jiangshan and Yang, Guoshuai and Zhou, Yanhui and Hou, Dan and Wang, Chuang and Hu, Yujie and Xia, Ying},
  title = {Olfactory Mucosal Mesenchymal Stem Cell‐Derived Exosomal LncA2M ‐ AS1 Ameliorates Parkinson's Disease by Regulating Microglial Glucose Metabolic Reprogramming and Neuroinflammation via the CFL1 / ROCK1 Axis},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2026},
  volume = {32},
  number = {7},
  doi = {10.1002/cns.71019}
}
Kostenlos starten →